Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02246764 · ClinicalTrials.gov registry record · Phase 3
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 93
- Enrollment target
NCT02246764: Completed Phase 3 study, sponsored by Aerie Pharmaceuticals.
NCT02246764 is a Phase 3 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 93 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02246764, a Phase 3 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the ocular and systemic safety of Netarsudil (AR-13324) Ophthalmic Solution, 0.02% q.d. and b.i.d. for 12 months compared to the active comparator Timolol Maleate Ophthalmic Solution, 0.5%.
Primary Outcome
Exposure to study medication in days for all treatment groups
Interventions
- OTHER Placebo
- DRUG AR-13324 Ophthalmic Solution 0.02%
- DRUG Timolol maleate Ophthalmic Solution 0.5% BID
- DRUG AR-13324 Ophthalmic Solution 0.02% BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
What the finished NCT02246764 record still lists
NCT02246764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02246764 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02246764 about?
NCT02246764 is a clinical study titled "Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension". The purpose of this study is to evaluate the ocular and systemic safety of Netarsudil (AR-13324) Ophthalmic Solution, 0.02% q.d. and b.i.d. for 12 months compared to the active comparator Timolol Maleate Ophthalmic Solution, 0.5%.
What is the current status of trial NCT02246764?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2014-09. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02246764?
The interventions under investigation include: Placebo (OTHER), AR-13324 Ophthalmic Solution 0.02% (DRUG), Timolol maleate Ophthalmic Solution 0.5% BID (DRUG), AR-13324 Ophthalmic Solution 0.02% BID (DRUG).
Who is sponsoring clinical trial NCT02246764?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02246764's enrollment target sits among peer trials
93 1722nd of 2000 higher than 278 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia